IMQ is an agonist of the toll-like receptor-7/8 (TLR-7/8) which has been approved for the treatment of actinic keratosis, external genital warts, and superficial basal cell carcinoma [13]. The gene discussed is TLR7; the disease is basal cell carcinoma.